Inhibition of angiogenesis through inhibition of vascular endothelial growth factor receptor 2
(VEGFR-2) has been applied in cancer therapy because of its important role in promoting …

A novel series of benzoxazole/benzothiazole derivatives 4a–c–11a–e were designed,
synthesized, and evaluated for anticancer activity against HepG2, HCT‐116, and MCF‐7 …

Novel series of phthalazine derivatives 6–11 were designed, synthesized, and evaluated for
their anticancer activity against two human tumor cell lines, HCT‐116 human colon …

Vascular endothelial growth factor-2 (VEGFR-2) is considered one of the most important
factors in tumor angiogenesis, and consequently a number of anticancer therapeutics have …

Three new series of 2‐phenyl benzimidazole‐based derivatives were designed,
synthesized, and evaluated for their in vitro cytotoxic activity against breast cancer (MCF‐7) …

In this study, novel VEGFR-2-targeting thiazolidine-2, 4-dione derivatives with potential
anticancer properties were designed and synthesized. The ability of the designed …

A new series of 2-aminobenzothiazole hybrids linked to thiazolidine-2, 4-dione 4a–e, 1, 3, 4-
thiadiazole aryl urea 6a–d, and cyanothiouracil moieties 8a–d was synthesised. The in vitro …

Four new nicotinamide-based derivatives were designed as antiangiogenic VEGFR-2
inhibitors. The congeners were synthesized possessing the pharmacophoric essential …

VEGFR-2 is a tyrosine kinase receptor for VEGFs that play a central role in tumor
angiogenesis. The inhibition of the tyrosine kinase domain of VEGFR-2 has become an …

One crucial strategy for the treatment of breast cancer involves focusing on the Vascular
Endothelial Growth Factor Receptor (VEGFR-2) signaling system. Consequently, the …